Targeting RSK4 prevents both chemoresistance and metastasis in lung cancer


Session type:


Stelios Chrysostomou1,Rajat Roy1,Filippo Prischi2,Katie Chapman3,Uwais Mufti4,Robert Peach1,Francesco Mauri1,Joel Abrahams1,Eric Aboagye1,Maruf Ali1,Michael Seckl1,Olivier Pardo1
1Imperial College London,2University of Essex,3Assay Biology, Domainex Ltd,4Department of Urology, Leeds Teaching Hospitals NHS Trust



Lung cancer is the primary cause of cancer death worldwide with a 5-year survival rate <5%. Non-small cell lung cancer (NSCLC) accounts for 85% of cases with adenocarcinoma being the major subtype. Patients almost invariably develop metastatic drug-resistant disease and this is responsible for our failure to provide curative therapy. Hence, a better understanding of the mechanisms underlying these biological processes is urgently required to improve clinical outcome.

The 90 kDa ribosomal S6 kinases (RSKs) are downstream effectors of the Ras/MAPK cascade. RSKs are highly conserved serine/threonine protein kinases implicated in diverse cellular processes, including cell survival, proliferation, migration and invasion. Four isoforms exist in humans (RSK1-4) that are uniquely characterised by the presence of two non-identical N- and C-terminus kinase domains.


Two kinome siRNA screens were performed to identify novel regulators of drug response and migration/invasion in lung and bladder cancer cells. RSK4 emerged as a novel regulator of both processes.


We show here that RSK4, contrary to RSK1, promotes both drug resistance and metastasis in lung cancer. This kinase is overexpressed in the majority of NSCLC biopsies and this correlates with poor overall survival in lung adenocarcinoma patients. The knockdown of RSK4 sensitises lung cancer cells to chemotherapy and prevents their migration and invasiveness in vitro and in vivo. RSK4 downregulation decreases the anti-apoptotic proteins Bcl2 and cIAP1/2 which correlates with increased apoptotic signalling. RSK4 silencing also induces mesenchymal-epithelial transition (MET) through inhibition of NFκB activity. A small-molecule inhibitor screen identified several floxacins, including trovafloxacin, as potent allosteric inhibitors of RSK4 activation. Trovafloxacin reproduced all effects of RSK4 silencing in vitro and in vivo and is predicted to bind a novel allosteric site revealed by our RSK4 N-terminal kinase domain crystal structure.


Taken together, our data demonstrate that RSK4 represents a promising novel therapeutic target in lung cancer.